Always private
DuckDuckGo never tracks your searches.
Learn More
You can hide this reminder in Search Settings
All regions
Argentina
Australia
Austria
Belgium (fr)
Belgium (nl)
Brazil
Bulgaria
Canada (en)
Canada (fr)
Catalonia
Chile
China
Colombia
Croatia
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India (en)
Indonesia (en)
Ireland
Israel (en)
Italy
Japan
Korea
Latvia
Lithuania
Malaysia (en)
Mexico
Netherlands
New Zealand
Norway
Pakistan (en)
Peru
Philippines (en)
Poland
Portugal
Romania
Russia
Saudi Arabia
Singapore
Slovakia
Slovenia
South Africa
Spain (ca)
Spain (es)
Sweden
Switzerland (de)
Switzerland (fr)
Taiwan
Thailand (en)
Turkey
Ukraine
United Kingdom
US (English)
US (Spanish)
Vietnam (en)
Safe search: moderate
Strict
Moderate
Off
Any time
Any time
Past day
Past week
Past month
Past year
  1. cordis.europa.eu

    FIGHT-DM1 is a project aimed at developing, ATX-01, a first-in-class oligo therapy for myotonic dystrophy type 1 (DM1). In order to relieve the health-related pains of patients, our project aims to clinically validate our proposed product, ATX-01, as a disruptive disease-modifying therapy for myotonic dystrophy type 1.
  2. Was this helpful?
  3. cordis.europa.eu

    Mar 7, 2023Results Fact Sheet Reporting Results Fact Sheet Reporting Results Project Information fight-dm1 Grant agreement ID: 190181217 DOI 10.3030/190181217 EC signature date 21 December 2022 Start date 1 January 2023 End date 30 June 2025 Funded under The European Innovation Council (EIC) € 20 074 282,53 EU contribution € 2 500 000,00 2 500 000,00
  4. cordis.europa.eu

    Mar 7, 2023Myotonic dystrophy type 1 (DM1) is a clinically and genetically heterogeneous disorder with more than 1 million diagnosed patients worldwide, making it the most common adult muscular dystrophy. Available treatments only relief symptoms. Given this need, we offer ATX-01, a...
  5. sciencedirect.com

    Mar 1, 2023The beginning of the 20th decade has witnessed an increase in drug development programs for myotonic dystrophy type 1 (DM1). We have collected nearly 20 candidate drugs with accomplished preclinical and clinical phases, updating our previous drug development pipeline review with new entries and relevant milestones for pre-existing candidates. Three interventional first-in-human clinical trials ...
  6. link.springer.com

    Jul 14, 2023Purpose of review This review aimed to summarize the clinical characteristics of myotonic dystrophy type 1 and to provide a comprehensive review of the current management options for DM1 patients. Recent findings Tremendous advances in understanding the molecular pathophysiology of the disease have led to the first successful preclinical or even clinical studies of disease-modifying therapies ...
  7. myotonic.org

    Drug Development Pipeline for Myotonic Dystrophy Type 1 (DM1) and Myotonic Dystrophy Type 2 (DM2) ... We appreciate all those developing new treatment options for DM patients and would be very thankful for any researchers who may have been Ben Porter at ben.porter@newcastle.ac.uk
  8. entradatx.com

    Our DM1 program is designed to address the underlying genetic cause of DM1 with the potential to restore function of an essential protein and its critical downstream products. 40,000+ people in the U.S have DM1. 1 50,000+ people in Europe have DM1. 1 Myotonic dystrophy type 1 - often referred to as DM1 - is a rare, multisystemic disease caused by excessive repeats of the nucleotide ...
  9. pubmed.ncbi.nlm.nih.gov

    Myotonic dystrophy, or dystrophia myotonica type 1 (DM1), is a multi-systemic disorder and is the most common adult form of muscular dystrophy. It affects not only muscles but also many organs, including the brain. Cerebral impairments include cognitive deficits, daytime sleepiness, and loss of visu …
  10. developmentaid.org

    Jan 1, 2023Objective: Myotonic dystrophy type 1 (DM1) is a clinically and genetically heterogeneous disorder with more than 1 million diagnosed patients worldwide, making it the most common adult muscular dystrophy. Available treatments only relief symptoms. Given this need, we offer ATX-01, a first in class miRNA therapy that inhibits miR-23b without changing the DNA, which rescues DM1 pathogenic mis ...
  11. pubmed.ncbi.nlm.nih.gov

    Myotonic dystrophy type 1 (DM1) is a multisystemic neuromuscular genetic disease with an estimated prevalence of approximately at least half a million individuals based on its vast ethnic variation. Building upon a well-known physiopathology and several proof-of-concept therapeutic approaches, herein we compile a comprehensive overview of the most recent drug development programs under ...
  12. Can’t find what you’re looking for?

    Help us improve DuckDuckGo searches with your feedback

Custom date rangeX